Every 10-Q that Boundless Bio, Inc. (BOLD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BOLD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BOLD filings page.
Boundless Bio, Inc. reported continued clinical‑stage losses with no product revenue. For the three and six months ended June 30, 2026, net loss was $23.7 million and $37.2 million, or $1.06 and $1.66 per share, respectively. Cash, cash equivalents and short‑term investments totaled $72.6 million, which management believes will fund operations for at least twelve months from issuance of these financial statements, without giving effect to the proposed merger or anticipated dividend.
On June 22, 2026, Boundless agreed to merge with Serapha Bio, Inc.. After closing, Serapha stockholders are expected to own 96.31% of the combined company and Boundless stockholders 3.69%, on a fully diluted basis. Closing is subject to stockholder approvals, continued Nasdaq listing, SEC effectiveness of a Form S‑4, and Serapha obtaining at least $200 million in related financings. Boundless expects to declare a pre‑closing cash dividend estimated at $44–48 million in aggregate for existing stockholders.
Boundless is pivoting away from its ecDNA‑directed oncology programs after trial data and pharmacokinetic exposure for lead candidate BBI‑940 were deemed insufficient to support further development. The company terminated its large San Diego headquarters lease, incurring $10.5 million in termination consideration and $1.6 million of asset impairments, and entered a smaller short‑term lease. It also announced a workforce reduction of approximately 75%, recording $2.8 million in severance charges and estimating total one‑time restructuring costs of $3–5 million. If the merger does not close, Boundless indicates it may seek alternative financings, other strategic transactions, or liquidation.
Boundless Bio, Inc. reported a Q1 2026 net loss of $13.6 million, narrowing from $15.8 million a year earlier, as it advances its lead ecDNA-directed cancer therapy BBI-940.
R&D expenses fell to $9.7 million and G&A to $4.7 million, reflecting portfolio and cost reductions.
Cash, cash equivalents, and short-term investments totaled $92.8 million, and the company currently expects this to fund operations into the second half of 2028.
Subsequent to quarter-end, Boundless Bio terminated its large San Diego headquarters lease with a $10.0 million payment plus forfeiture of a $0.5 million deposit, and signed a much smaller 10,822-square-foot La Jolla lease at about $56,000 per month, expecting a related non-cash charge of approximately $2.4 million in Q2 2026.
Boundless Bio (Nasdaq: BOLD) filed its Q3 report and posted a net loss of $13.9 million. Operating expenses were $15.1 million, driven by research and development of $10.7 million and general and administrative of $4.5 million. Interest income was $1.3 million.
Liquidity remained solid with $117.6 million in cash, cash equivalents, and short‑term investments as of September 30, 2025. Management states this supports operations into the first half of 2028. The company has an at‑the‑market equity program of up to $14.5 million; no shares were sold under the program as of September 30, 2025.
Pipeline updates center on the POTENTIATE study: the BBI‑355 (CHK1 inhibitor) and BBI‑825 (RNR inhibitor) combination arm opened for enrollment in Q3 2025. Earlier monotherapy and third‑party combo arms of BBI‑355 were wound down in May 2025 as part of a portfolio prioritization and cost streamlining. Beyond the lead program, the company selected BBI‑940 (Kinesin degrader) as a development candidate and expects to submit an IND and start first‑in‑human testing in the first half of 2026. Shares outstanding were 22,385,611 as of October 31, 2025.
Overview: Boundless Bio (Nasdaq: BOLD) is a clinical-stage precision oncology company focused on ecDNA-directed therapeutics (ecDTx). The company reported no revenue and an accumulated deficit of $232.9 million as of June 30, 2025.
Key financials (as of/for June 30, 2025): Cash and cash equivalents of $14.7 million, short-term investments of $112.5 million (total cash, cash equivalents and short-term investments of $127.1 million). Net loss was $31.4 million for the six months ended June 30, 2025 and $15.7 million for the quarter ended June 30, 2025. Operating cash used was $26.4 million for the six months ended June 30, 2025.
Operational and program updates: Company completed portfolio prioritization May 23, 2025, discontinued certain single-agent arms of BBI-355 and halted escalation of BBI-825 dosing, opened a BBI-355/BBI-825 combination arm in the POTENTIATE trial, selected kinesin degrader development candidate BBI-940 with an expected IND submission in H1 2026, and implemented a workforce reduction of approximately one-third. Management expects existing cash, cash equivalents, and short-term investments to fund operations into the first half of 2028.